Bleomycin

J Clin Oncol 2000 18 854-859 PREMEDICATIONS 1. Kytril 1 mg PO IV 30 minutes before and 12 hours after chemotherapy on days 1 and 8 2. Dexamethasone 20 mg IV 30 minutes before chemotherapy on days 1 and 8 1. Give cisplatin delayed-emesis prophylaxis Repeat every 14 days Cisplatin vigorous hydration is required can be nephrotoxic and ototoxic can cause peripheral neuropathy hold or reduce for creatinine > 1.5 Dactinomycin vesicant-watch for extravasation Methotrexate use 75...

Chemotherapy Regimens and Cancer Care

VADEMECUM Chemotherapy Regimens and Cancer Care LANDES BIOSCIENCE Georgetown, Texas U.S.A. Copyright 2001 Landes Bioscience All rights reserved. No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. Please address all inquiries to the Publisher Landes Bioscience, 810 S. Church Street, Georgetown, Texas, U.S.A....

Hematologic Malignancies

Chronic Lymphocytic Leukemia Chronic Myelogenous Leukemia Vincristine 2 mg IV days 1,8,15,22 Daunorubicin 25 mg M2 IV days 1,8,15,22 Prednisone 60 mg M2 PO days 1-28 L-asparaginase 5,000 units M2 IV days 1-14 Cyclophosphamide 650 mg M2 IV days 29,43,57 -maximum dose 1000 mg 6-Mercaptopurine 60 mg M2 PO days 29-57 Methotrexate 10 mg M2 IT days 31,38,45,52 -maximum dose is 15 mg Cranial 1800-2400 cGy given with phase II radiotherapy induction CONSOLIDATION PHASE I-begins week 20 Vincristine 2 mg...

Cervical Cancer

BIP 1 bleomycin ifosfamide cisplatin Bleomycin Ifosfamide Cisplatin Mesna 15 mg 1QQQ mg M2 5Q mg M2 1QQQ mg M2 REF Kumar et al. Gynecol Oncol 1991 4Q 1Q7-111 1. Kytril 1 mg PO IV 30 minutes before and 12 hours after chemotherapy on days 1-5 2. Dexamethasone 10 mg IV 30 minutes before chemotherapy on days 1-5 1. Give cisplatin delayed-emesis prophylaxis Cisplatin vigorous hydration is required can be nephrotoxic and ototoxic can cause peripheral neuropathy hold or reduce for creatinine gt 1.5...

Dose administration malaise myalgias fatigueDLT for lowdose administration

-bone marrow suppression -nausea and vomiting -mucocutaneous effects stomatitis, mucositis -cardiovascular effects arrhythmias, hypotension -anorexia -mental status changes confusion, lethargy, psychosis -renal impairment Altretamine -alkylating agent hexamethyl- -nausea and vomiting melamine -bone marrow suppression -diarrhea, abdominal cramps -mucocutaneous effects stomatitis, mucositis -neuropathies -mental status changes -cytoprotectant free radical scavenger -nausea and vomiting...

Mesna

Eur J Cancer 1990 26 558-561 -there are multiple variations of this regimen 1. Kytril 1 mg PO IV 30 minutes before chemotherapy and Q12H for 3 additional doses 2. Dexamethasone 20 mg IV on days 1 and 2 Doxorubicin monitor cumulative dose for cardiac toxicity not to exceed 550 mg M2 or 450 mg M2 with prior chest radiotherapy vesicant avoid extravasation use 50 for bilirubin 1.5-3.0 use 25 for bilirubin gt 3.0 Ifosfamide adequate hydration is necessary to prevent nephrotoxicity...

Gemcitabine

Am J Clin Oncol 1998 21 505-508 Repeat every 28 days Gemcitabine 1000 mg M2 IV days 1,8,15 REF Crino et al. J Clin Oncol 1999 17 2081-2085 PREMEDICATIONS 1. Compazine 10 mg PO IV 30 minutes before chemotherapy Repeat every 28 days Topotecan Topotecan 1.5 mg M2 d IV over 30 min days 1-5 REF Perez-Soler et al. J Clin Oncol 1996 14 503-13 PREMEDICATIONS 1. Kytril 1 mg PO IV 30 minutes before and 12 hours after chemotherapy on days 1-5 2. Dexamethasone 20 mg IV 30 minutes...

Cisplatin gemcitabine

J Clin Oncol 1999 17 25-30 1. Kytril 1 mg PO IV 30 minutes before and 12 hours after chemotherapy on day 1 2. Dexamethasone 20 mg IV 30 minutes before chemotherapy on day 1 3. Compazine 10 mg PO IV 30 minutes before chemotherapy on days 8 and 15 1. Give cisplatin delayed-emesis prophylaxis Cisplatin vigorous hydration is required can be nephrotoxic and ototoxic can cause peripheral neuropathy hold or reduce for creatinine gt 1.5 REF Chahinian et al. J Clin Oncol 1993 11...